Surviving Sepsis and Stewardship
|
|
- Tyrone Sharp
- 6 years ago
- Views:
Transcription
1 Surviving Sepsis and Stewardship Start Smart Then Focus Are these hopelessly compe5ng objec5ves? Dr David R Jenkins, Consultant Medical Microbiologist and Infec>on Control Doctor, University Hospitals of Leicester NHS Trust & Honorary Reader, University of Leicester Medical School david.jenkins@uhl-
2 Some unpleasant truths All exposure of bacteria to an>microbials An>microbial resistance Resistance is effec>vely irreversible New an>microbial development is stalled
3 Delayed effec5ve an5bacterial treatment in sep5c shock is lethal Kumar A et al. Dura5on of hypotension before ini5a5on of effec5ve an5microbial therapy is the cr5cal determinant of survival in human sep5c shock. Crit Care Med 2006;34:
4 The sepsis challenge Sepsis is lethal Delays in effec>ve an>bio>c treatment increase risk of dying Microbiological diagnosis and suscep>bility tes>ng of causa>ve organisms takes hours at best. So use empirical broad- spectrum an>bacterials BUT. This increases resistance
5 The de- escala5on compromise 1. Start with broad- spectrum empirical an>bacterial treatment (single agent or combina>on) 2. Use culture results to: Switch to narrow spectrum single agent, or Drop redundant component of combina>on 3. Hope you haven t done too much ecological damage
6 Start Smart - this means: do not start an>microbial therapy unless there is clear evidence of infec>on take a thorough drug allergy history ini>ate prompt effec>ve an>bio>c treatment within one hour of diagnosis (or as soon as possible) in pa>ents with severe sepsis or life threatening infec>ons. Avoid inappropriate use of broad spectrum an>bio>cs comply with local an>microbial prescribing guidance document clinical indica>on (and disease severity if appropriate), drug name, dose and route on drug chart and in clinical notes include review/stop date or dura>on obtain cultures prior to commencing therapy where possible (but do not delay therapy) prescribe single dose an>bio>cs for surgical prophylaxis where an>bio>cs have been shown to be effec>ve document the exact indica>on on the drug chart (rather than sta>ng long term prophylaxis) for clinical prophylaxis ESPAUR SSTF Implementa5on subgroup. Start Smart- Then Focus. An5microbial Stewardship Toolkit for English Hospitals. (2015) Public Health England
7 Then Focus - this means: reviewing the clinical diagnosis and the con>nuing need for an>bio>cs at hours and documen>ng a clear plan of ac>on - the an>microbial prescribing decision the five an>microbial prescribing decision op>ons are: 1. Stop an>bio>cs if there is no evidence of infec>on 2. Switch an>bio>cs from intravenous to oral 3. Change an>bio>cs - ideally to a narrower spectrum or broader if required 4.Con>nue and document next review date or stop date 5.Outpa>ent Parenteral An>bio>c Therapy (OPAT) it is essen>al that the review and subsequent decision is clearly documented in the clinical notes and on the drug chart where possible eg stop an>bio>c ESPAUR SSTF Implementa5on subgroup. Start Smart- Then Focus. An5microbial Stewardship Toolkit for English Hospitals. (2015) Public Health England
8 Is Start Smart Then Focus SMART?
9 What does smart mean? Smart vi To feel or be the loca-on of a prolonged s-nging pain; to be punished (for) vt To cause to smart n A smar-ng pain; smart money; a dandy adj Sharp and s-nging; brisk; acute, wi?y; clever, brainy; pert, vivacious; trim, spruce, fine; fashionable; keen, quick and efficient in business; technologically advanced and able to respond to changing condi-ons; computer- guided or electronically controlled as in smart house, smart bomb, smart weapon. The Chambers Dic5onary 10 th edi5on (2006)
10
11
12
13 Ques5ons 1. Does SSTF lead to accurate use of empirical broad spectrum an>bacterials? 2. Are de- escala>on decisions made appropriately? 3. Does de- escala>on lead to non- inferior outcomes compared with con>nued broad spectrum treatment? 4. What will happen if SSTF doesn t deliver?
14 Does SSTF lead to accurate use of empirical broad spectrum an5bacterial therapy? SSTF depends on ability of clinicians to: Accurately diagnose sepsis Iden>fy infec>on focus Iden>fy clinical features linked to raised risk of resistant causa>ve organism/s OR give everyone a carbapenem
15 UK Sepsis Trust Inpa5ent Sepsis Screening and Ac5on Tool (2016) Begs the ques>on, is the pa>ent infected? Are front line junior doctors competent to decide?
16 European medical students a`tudes and percep5ons Online survey of the knowledge and perspec>ves of medical students in seven European medical schools (Dundee, Geneva, Linkoping, Ljubljana, Madrid, Nice, Oxford) The majority of students at six of the seven medical schools wanted more an>bio>c educa>on. However, only a minority of Oxford students wanted more. Dyar OJ et al. European medical students: a first mul5centre study of knowledge, a`tudes and percep5ons of an5bio5c prescribing and an5bio5c resistance. J An5microb Chemother 2014;69:
17 Empiric choices for sepsis treatment and associated outcomes - Spanish experience DCCT = different- class combina>on therapy Mortality rate significantly lower in pa>ents given DCCTs than those given non- DCCTs (34% versus 40%, P=0.042) Diaz- Mar>n A et al. An>bio>c prescrip>on pakerns in the empiric therapy of severe sepsis: combina>on of an>microbials with different mechanisms of ac>on reduces mortality. Cri>cal Care 2012;16:R223
18 What we say to junior doctors: Don t jump straight to meropenem. Assess the pa>ent, take appropriate cultures, treat according to the an>microbial guidance, only use meropenem for severe sepsis if appropriate What they hear: Blah blah blah blah blah meropenem blah blah blah blah blah blah meropenem blah blah blah blah blah Gary Larson
19 What s happening in Leicester? DDD/1000 bed days Surviving sepsis campaign started
20 Are de- escala5on decisions made appropriately? Are appropriate microbiological samples collected prior to an>bacterial treatment? Do clinicians act on results?
21 Survey of carbapenem use in French hospitals in pa>ents received carbapenems 52.6% of use was empirical, mainly because of severe sepsis. Median dura>on of empiric treatment was 6 days, 25% received empiric treatment for > 10 days. De- escala>on occurred in only 23% of pa>ents treated empirically, unless an an>bio>c consultant intervened when the de- escala>on rate was 35%. Nearly half of pa>ents were without posi>ve microbiological results to guide de- escala>on Gauzit R et al. Carbapenem use in French hospitals: A na5onwide survey at the pa5ent level. Int J An5microb Agents 2015;46:
22 Does de- escala5on lead to non- inferior outcomes compared with con5nued broad spectrum treatment? Is there good evidence that de- escala>on doesn t cause pa>ent harm or increased resource use?
23 De- escala5on of an5microbial treatment for adults with sepsis, severe sepsis or sep5c shock Cochrane Collabora>on systema>c review of effec>veness and safety of de- escala>on an>microbial treatment for adult pa>ents diagnosed with sepsis, severe sepsis or sep>c shock Search strategy retrieved 493 studies. No published RCTs tes>ng de- escala>on were iden>fied. One ongoing RCT was found No adequate direct evidence of effec>veness or safety of de- escala>on. Silva BNG et al. De- escala5on of an5microbial treatment for adults with sepsis, severe sepsis or sep5c shock. Cochrane Database of Systema5c Reviews Issue 3 Art No CD007934
24 RCT of de- escala5on versus con5nua5on of empirical treatment in severe sepsis Interven>on Randomised controlled trial of de- escala>on versus con>nua>on of empirical an>bio>c treatment in pa>ents with severe sepsis in 9 French ICUs Results De- escala>on pa>ents had longer ICU stays (14.9 versus 12.1 days) De- escala>on pa>ents had more super- infec>ons (27% versus 11%) De- escala>on pa>ents had more an>bio>c treatment days (14.1 versus 9.9 days) All above P<0.05 Leone M et al. De- escala5on versus con5nua5on of empirical an5microbial treatment in severe sepsis: a mul5center non- blinded randomized noninferiority trial. Intensive Care Med 2014;40:
25 De- escala5on linked to possible under- treatment Simula>on study of pharmacokine>cs of β- lactam an>bio>cs in pa>ents with severe sepsis Time for which an>bio>c concentra>on exceeds MIC calculated (ft >MIC ) Broad- spectrum β- lactams: Meropenem Piperacillin- tazobactam ft >MIC >89% for all simula>ons Narrower- spectrum β- lactams: E coli Co- amoxiclav ft >MIC 85% Cefuroxime ft >MIC 65% Staph aureus Flucloxacillin ft >MIC 74% Cefepime ft >MIC 88% Cefazolin ft >MIC 90% Carlier M et al. A simula5on study reveals lack of pharmacokine5c/pharmacodynamic target akainment in de- escalated an5bio5c therapy in cri5cally ill pa5ents. An5microb Agents Chemother 2015;59:
26 What will happen if SSTF doesn t deliver?
27 The rise in carbapenem- resistant Klebsiella pneumoniae across Europe 2008 Source:EARS- Net
28 The rise in carbapenem- resistant Klebsiella pneumoniae across Europe 2010 Source:EARS- Net
29 The rise in carbapenem- resistant Klebsiella pneumoniae across Europe 2012 Source:EARS- Net
30 The rise in carbapenem- resistant Klebsiella pneumoniae across Europe 2014 Source:EARS- Net
31 What will happen to an5bacterial efficacy on the back of Surviving Sepsis?
32
33 What should we do? Insist on sufficient curriculum >me for medical student an>microbial prescribing Is a medical degree sufficient licence to prescribe an>microbials? Increase presence of an>microbial prescribing exper>se on wards Make inappropriate an>microbial prescribing an odious offence
Guess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationSepsis and Antimcrobial Stewardship: Are they really mutually Exclusive?
Sepsis and Antimcrobial Stewardship: Are they really mutually Exclusive? DR KATE ADAMS CONSULTANT INFECTIOUS DISEASES HULL AND EAST YORKSHIRE NHS TRUST AMS Sepsis No! At least not if the sepsis programme
More informationHAP/VAP care bundle interventions - a UK approach. Dr R G Masterton NHS Ayrshire & Arran
HAP/VAP care bundle interventions - a UK approach Dr R G Masterton NHS Ayrshire & Arran How Hazardous Is Health Care? (Leape and Amalberti) Total lives lost per year 100,000 10,000 1,000 100 10 1 HAZARDOUS
More informationWhat are the key challenges in implementing Stewardship the AMS team view
What are the key challenges in implementing Stewardship the AMS team view Philip Howard Consultant Pharmacist Twitter: AntibioticLeeds philip.howard2@nhs.net www.england.nhs.uk/ourwork/patientsafety/amr
More informationIMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016
Where did we start? Where did we get to? Where do we want to go? IMPROVING GLOBAL ESTIMATES: PROCESS AND MILESTONES IATT Webinar June 7 th 2016 Mar6na Penazzato Paediatric advisor HIV Department WHO, Geneva-
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationAntibiotic Use in the Outpatient Setting. Ryan Bariola, MD FIDSA Visi4ng Clinical Associate Professor of Medicine
Antibiotic Use in the Outpatient Setting Ryan Bariola, MD FIDSA Visi4ng Clinical Associate Professor of Medicine Nothing to disclose Disclosures Case 43 year old pa4ent schedules appointment for cough
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationGuidelines. 14 Nov Marc Bonten
Guidelines 14 Nov 2014 Marc Bonten Treatment of Community-Acquired Pneumonia SWAB/ NVALT guideline 2011, replaced SWAB guideline 2005 Empirical treatment must cover the most likely causative pathogen.
More informationNew Medicines Committee Briefing. July Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection
New Medicines Committee Briefing July 2014 Fosfomycin trometamol for the treatment of multidrug resistant urinary tract infection (unlicensed indication) Fosfomycin trometamol to be reviewed for use within:
More informationIndependence Well- being and Choice 2005, Our health, our care, our say 2006, Strong and Prosperous 2006
Medicines Op+misa+on Outcome focused approach to safe and effec+ve use of medicines that takes into account the pa+ent s values, percep+on and experience of taking their medicines Important Outcomes for
More informationThe Infection Control Doctor and Clostridium difficile infection. Dr David R Jenkins University Hospitals of Leicester NHS Trust, England
The Infection Control Doctor and Clostridium difficile infection Dr David R Jenkins University Hospitals of Leicester NHS Trust, England 250 200 150 100 50 0 Monthly cases of Clostridium difficile (UHL
More informationThe problem with an0bio0cs. Oct CCST Council Mee0ng Mar0n J. Blaser, MD New York University
The problem with an0bio0cs Oct 27 2015 CCST Council Mee0ng Mar0n J. Blaser, MD New York University Br J Exp Pathol 1929;79:780. J Clin Invest 1945;24:589. Top 8 prescrip0ons in US children, 2010 Prescrip0on
More informationOverview of research lines at De Viersprong. Joost Hutsebaut, Dawn Bales et al MBT-mee?ng Vienna 2016
Overview of research lines at De Viersprong Joost Hutsebaut, Dawn Bales et al MBT-mee?ng Vienna 2016 The beginning 2004: start of DH MBT-program at de Viersprong Replica?on of original AFC-program Excellent
More informationSponsored by Virox Technologies Inc. C. difficile 101 A brief review of guidelines and controversies
Controlling Clostridium difficile Outbreaks: Going Beyond the Guidelines Michael Gardam Infec
More informationOutline. Pharmacists Improving Outcomes in the Management of. of Infectious Diseases. Threats Against Desired Outcomes 7/11/2010
Pharmacists Improving Outcomes in the Management of Infectious Diseases Christine Teng, MSc(Clin Pharm) BCPS Assistant Professor Dept of Pharmacy, National University of Singapore Principal Pharmacist
More informationOrchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department
Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Dr. Eugene Tso Division of Infectious Diseases Department of Medicine & Geriatrics United Christian Hospital 11 May 2010
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationEnglish Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Figures Slideset
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Figures Slideset The 5-year UK AMR strategy Key aims improving infection prevention and control practices optimising
More informationUsing Implementation Science to Address Prevention of Mother to Child Transmission of HIV
Using Implementation Science to Address Prevention of Mother to Child Transmission of HIV Dr. Laura Guay Vice President for Research Elizabeth Glaser Pediatric AIDS Founda@on 1 The role of Implementation
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationSkin and So) Tissue Infec1ons: MRSA and Beyond
Overview Skin and So) Tissue Infec1ons: MRSA and Beyond Catherine Liu, M.D. Assistant Clinical Professor Division of Infec1ous Diseases University of California, San Francisco 2011 IDSA MRSA Treatment
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationDebate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza Aeron Hurt WHO Collabora@ng Centre for Reference and Research on Influenza, Melbourne, Australia www.influenzacentre.org NA inhibitor
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationPILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS
PILOT STUDY PROPOSAL FOR EARLY DISCHARGE OF LOW-RISK NEUTROPENIC PATIENTS RATIONALE: It is increasingly being recognised that not all neutropenic patients have the same risk of complications during episodes
More informationCare of Diabe+c Pa+ents in the Hospital Se6ng
Care of Diabe+c Pa+ents in the Hospital Se6ng 1/11/2011 Kathia Desronvil, BSN, MSN, FNP- BC Hospitalist, Internal Medicine Department Nash General Hospital Rocky Mount, NC 27616 (H) 919-890- 5561; (C)
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationDiscordant MIC Analysis: Tes5ng for Superiority within a Non- inferiority Trial
Discordant MIC Analysis: Tes5ng for Superiority within a Non- inferiority Trial Dean Follmann, Erica BriDain, and John Powers Na5onal Ins5tute of Allergy and Infec5ous Diseases November 19, 2014 1 Current
More informationThe Role of PCP in Prostate Cancer Screening Beaver Creek Ma< T. Rosenberg
The Role of PCP in Prostate Cancer Screening Beaver Creek 2017 Ma< T. Rosenberg A Cri@cal Look at the Historical Flow Pa@ent concern Office visit History DRE PSA Biopsy Specimen with pathologist Too Many
More informationOncology Care Model Overview
Oncology Care Model Overview Centers for Medicare & Medicaid Services Innova3on Center (CMMI) September 2017 Innova3on at CMS Center for Medicare & Medicaid Innova3on (Innova3on Center) Established by
More informationThe future of ARIA guidelines
The future of ARIA guidelines Evidence- based medicine GRADE Recommenda
More informationDevelopment of C sporins. Beta-lactam antibiotics - Cephalosporins. Second generation C sporins. Targets - PBP s
Beta-lactam antibiotics - Cephalosporins Development of C sporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability properties
More informationTop Curbside Consult Ques7ons in Inpa7ent ID
Top Curbside Consult Ques7ons in Inpa7ent ID Management of the Hospitalized Pa7ent October 2014 Jennifer Babik, MD, PhD Assistant Clinical Professor Division of Infec7ous Diseases, UCSF Disclosures! I
More informationLAI: Linee guida ed esperienze internazionali
LAI: Linee guida ed esperienze internazionali LAI: Guidelines and interna5onal experience PM Llorca CHU Clermont-Ferrand EA 7280 Université Clermont Auvergne Disclosures Advisory board: Allergan, Jansen,
More informationUpper Extremity Fractures and Secondary Fall Prevention: Opportunities to Improve Management and Outcomes Across Disciplines.
Upper Extremity Fractures and Secondary Fall Prevention: Opportunities to Improve Management and Outcomes Across Disciplines Chris,ne McDonough, PhD, PT, CEEAA Health Outcomes Unit Department of Health
More informationWelcome! Pragmatic Clinical Studies. David Hickam, MD, MPH Program Director Clinical Effectiveness Research. David Hickam, MD, MPH
Pragmatic Clinical Studies David Hickam, MD, MPH Program Director Clinical Effec2veness Research June 23, 2015 Welcome! David Hickam, MD, MPH Program Director Clinical Effectiveness Research 2 In this
More informationEXAMPLE ABSTRACT REASONING. Medicine and Abstract Reasoning - Example 1. One 2 One Medicine UKCAT Preparation Day
ABSTRACT REASONING Medicine and Abstract Reasoning - Example 1. The similari+es and subtle differences between biochemical structures is the bases of pharmacology - the study of medica+ons. Below we see
More informationFindings from the At Home / Chez Soi Demonstration Project in Canada. Paula Goering and Catharine Hume May 2, 2013
Findings from the At Home / Chez Soi Demonstration Project in Canada Paula Goering and Catharine Hume May 2, 2013 Outline for today Overview of Project Design Na8onal level findings re one year outcomes
More informationPragma&c Clinical Trials
Pragma&c Clinical Trials Susanne May, PhD Associate Professor Department of Biosta&s&cs, School of Public Health, University of Washington Preliminaries PLEASE ask ques&ons at any &me REALLY good clinical
More informationSepsis. Reliability- can we achieve Dr Ron Daniels
Sepsis. Reliability- can we achieve it? @SepsisUK Dr Ron Daniels Chief Executive, Global Sepsis Alliance Fellow: NHS Improvement Faculty Chief Executive: United Kingdom Sepsis Trust & Chair, UK SSC RRAILS
More informationNova StatStrip Blood Glucose Meter Re-Cer7fica7on 2017
SUNY Downstate Medical Center University Hospital of Brooklyn Point of Care Laboratory & Department of Nursing Services Ins7tute of Con7nuous Learning Nova StatStrip Blood Glucose Meter Re-Cer7fica7on
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationInfective Endocarditis Empirical therapy Antibiotic Guidelines. Contents
Infective Endocarditis Empirical therapy Antibiotic Guidelines Classification: Clinical Guideline Lead Author: Antibiotic Steering Group Additional author(s): as above Authors Division: Division of Clinical
More informationDiabetes Self- management Educa4on and Support (DSME/S)
Improving Patient Care Through Diabetes Self- management Education Davida F. Kruger, MSN, APN-BC, BC-ADM Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone
More informationPsychological outcomes of cri2cal illness for pa2ents and family members. Erin K. Kross, MD Summer Lung Day June 18, 2010
Psychological outcomes of cri2cal illness for pa2ents and family members Erin K. Kross, MD Summer Lung Day June 18, 2010 Outline Overview of psychological outcomes for pa2ents and family members ager cri2cal
More informationProspective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital
Prospective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital Final Results Nathan Beahm, BSP, PharmD(student) September 10, 2016 Objectives Review background information
More informationBronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing
National Institute for Health and Care Excellence Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing Evidence review NICE guideline NG117 December 2018 Disclaimer The
More information10/26/15. Perspec'ves on maternal opioid use and abuse. Dr. Rita J. Nutt. Our Expectation. Harsh Realities
10/26/15 Perspec'ves on maternal opioid use and abuse Dr. Rita J. Nutt Our Expectation Harsh Realities 1 Opioid Abuse and Dependence Statistics, 2013 4.5 million people in the US current non- medical users
More informationβ-lactamase inhibitors
β-lactamase inhibitors Properties, microbiology & enzymology DAVID M LIVERMORE Professor of Medical Microbiology, UEA Lead on Antibiotic Resistance, Public Health England β-lactamase classes A B C D Serine
More informationHospital Communicable Diseases Surveillance Protocols Primer. Key Infec:on Preven:on and Control Lapses in the Clinical Office
OEMAC 33 rd Scien/fic Conference September 29, 2015; 2:50-3:15 Hospital Communicable Diseases Surveillance Protocols Primer Key Infec:on Preven:on and Control Lapses in the Clinical Office Se@ng Dr. Maureen
More informationControl and management of MRSA
Control and management of MRSA Daniel Kaul M.D. Associate Professor Director, ID Fellowship Program and Transplant ID service Division of Infec?ous Diseases University of Michigan Topics MRSA an?microbial
More informationWhat s New in Infec4ous Diseases? Azithromycin for Preven4on of Exacerba4ons of COPD 2/20/12. Azithromycin for Management of Chronic Illness
What s New in Infec4ous Diseases? Catherine Liu, M.D. Assistant Professor Division of Infec4ous Diseases University of California, San Francisco Azithromycin for Preven4on of Exacerba4ons of COPD Azithromycin
More information1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy
1. ATHENA Network, AVAC, and Salamander Trust with UN Women, undertook this mul>-stage review of the global status of access to an>retroviral therapy (ART) for women living with HIV 2. This is the first
More informationNeutropenic Sepsis Acute General Management and Support. Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology
Neutropenic Sepsis Acute General Management and Support Ernie Marshall Macmillan Consultant in Medical Oncology Clatterbridge Centre for Oncology Who Am I? I am A Medical Oncologist (MCCN) Site specialist
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationRespiratory Tract Infec1ons Long Term Care. Dr Karsten Hammond Infec1ous Diseases 28 March 2015
Respiratory Tract Infec1ons Long Term Care Dr Karsten Hammond Infec1ous Diseases 28 March 2015 Disclosures I have no financial rela1onships to disclose 82 yo Female In LTC for two years, total care from
More informationToday, we are going to introduce the discipline of sociology and look at the three major sociological perspec9ves, which will inform our further
Today, we are going to introduce the discipline of sociology and look at the three major sociological perspec9ves, which will inform our further study of culture. A=er that, we will define culture and
More informationEngage and Empower Pa.ents with Interac.ve Technology. Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012
Engage and Empower Pa.ents with Interac.ve Technology Northeast NAHAM Regional Conference Pa.ent Access: GeBng It Right Upfront October 22-23, 2012 NAHAM - Pa.ent Access Services 2 Pa%ent Access Services
More informationTuberculosis: What's new in diagnos6cs and management?
Tuberculosis: What's new in diagnos6cs and management? Colin Menezes, Department of Internal Medicine, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand. Objec6ves of this talk:
More informationUnderstanding. Design & Sta/s/cs. in Clinical Trials
Understanding Design & Sta/s/cs in Clinical Trials 1 Why bother? 2 Experience- Based Medicine? Benjamin Rush Father of American Psychiatry 3 Experience- Based Medicine? Supported blood- lejng as treatment
More informationSuppor&ng the Mental Health of Looked- A7er Children Across the Primary- Secondary Transi&on
Suppor&ng the Mental Health of Looked- A7er Children Across the Primary- Secondary Transi&on Helen Drew, & Robin Banerjee (University of Sussex), Mary John (University of Surrey) and Nikki Luke & Judy
More informationNICE Guidance. NICE Guidance Complicated urinary tract infections: ceftolozane/tazobactam. Full Evidence Summary
This National Institute for Health and Care Excellence (NICE) guidance is the current, unaltered NICE guidance at time of publication. BJUI publishes selected NICE guidance relevant to urologists to extend
More informationTime is Muscle. In this talk, I will address 3 ques7ons: School of Rehabilita?on Science Reaching Further
School of Rehabilita?on Science Reaching Further Time is Muscle Michelle Kho, PT, PhD Canada Research Chair in Cri?cal Care Rehabilita?on and Knowledge Transla?on McMaster University, Hamilton, ON Clinician
More informationSt. Louis Regional Asthma Coalition
Session 25 Update-Emergent Care of Students with Asthma for 20 th Annual Missouri Coordinated School Health Coalition Conference November 30, 2012 William L. Kincaid, MD, MPH 314-780-7635 WLKINCAID@swbell.net
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationLongitudinal regional analyses of an1bio1c consump1on in statutory health care insured pa1ents in Germany since 2008
Longitudinal regional analyses of an1bio1c consump1on in statutory health care insured pa1ents in Germany since 2008 Jörg Bätzing- Feigenbaum - Maike Schulz - Mandy Schulz - Jana Gisbert Miralles - Dominik
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Principal Clinical Scientist in Microbiology Director of the Hospital Infection Research Laboratory Associate Director of Infection Prevention and Control
More informationPotential Conflicts of Interests
Potential Conflicts of Interests Research Grants Agency for Healthcare Research and Quality Akers Bioscience, Inc. Pfizer, Inc. Scientific Advisory Boards Pfizer, Inc. Cadence Pharmaceuticals Kimberly
More informationA Retrospective Cross- sectional Study Evaluating Beta- lactam Allergy Labeling in Hospitalized Patients
Pharmacy Residency Research Project Manuscript A Retrospective Cross- sectional Study Evaluating Beta- lactam Allergy Labeling in Hospitalized Patients Bingjie (Amy) Wang Pharmacy Resident Trillium Health
More informationMedication Adherence Campaign Target Market Tracking Survey Results National Consumers League October 9, 2015
Medication Adherence Campaign Target Market Tracking Survey Results National Consumers League October 9, 2015 Objectives An ini%al target market survey was launched in May 2011 to serve as a benchmark
More informationHousekeeping Reminders
Housekeeping Reminders Thank you to Achaogen for their unrestricted educa2onal grant in support of this program To receive credit, please complete your CE Program Form or see instruc>ons in the program
More informationWHO posi)on paper on hepa))s A vaccines
WHO posi)on paper on hepa))s A vaccines Geneva, Switzerland Published in the Weekly Epidemiological Record on 13 July 2012 Transmission and incidence Hepa))s A virus (HAV) is transmiled primarily via the
More informationTo have loved and lost: A group for students who have lost a loved one
To have loved and lost: A group for students who have lost a loved one 1 Background Informa;on A bereaved person is grieving the loss of someone (or something) he or she valued Loss can nega;vely impact
More informationHHS. Hyperglycaemic Hyperosmolar State Care Pathway 1 Presenta8on to 6 hours. Page 1 of 2 AFFIX PATIENT LABEL ! INFORM DIABETES TEAM OF ADMISSION!
Hyperglycaemic Hyperosmolar State Care Pathway 1 Presenta8on to 6 hours Page 1 of 2 Time of Arrival Loca8on Date / / Diagnosis the characteris8c features of a person with HHS are a) Hypovolaemia b) Marked
More informationMDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationFunctional Design Targets! Hospital Infection Control!
2017 Healthcare Surfaces Summit Functional Design Targets! Hospital Infection Control! Max Munn, CEO and Founder Munnworks, LLC Problem: Sinks in hospital bathrooms are major source of microbes that cause
More informationClinical Staging and the At-Risk Phase of Psychotic Disorder
Clinical Staging and the At-Risk Phase of Psychotic Disorder Sabina Abidi MD FRCPC IWK Youth Psychosis Program Capital Health Nova ScoCa Early Psychosis Program Key Findings in Early Psychosis Knowledge
More informationClostridium difficile coli%s. John K. Midturi January 2013
Clostridium difficile coli%s John K. Midturi January 2013 Objec%ves Describe pathogenesis of C. Diff coli%s Review methods of diagnosis of C. Diff coli%s Discuss treatment op%ons first episode refractory
More informationDr Una Ni Riain, Consultant Microbiologist Ms Marie Tierney, Antimicrobial Pharmacist Galway University Hospitals
Dr Una Ni Riain, Consultant Microbiologist Ms Marie Tierney, Antimicrobial Pharmacist Galway University Hospitals Background Usage of meropenem in our hospital has doubled over the past seven years from
More informationDecision Support. HAP 752 Advanced Health Informa6on Systems. Janusz Wojtusiak, PhD George Mason University Spring 2014
Decision Support HAP 752 Advanced Health Informa6on Systems Janusz Wojtusiak, PhD George Mason University Spring 2014 Evidence does not make decisions, people do. - Haynes, Devereaux, GuyaQ (BMJ 2002)
More informationLegal Aspects in Intravenous Nutrient Therapy. Nayan Patel PharmD
Legal Aspects in Intravenous Nutrient Therapy Nayan Patel PharmD Objec;ves Understand state to state varia4on in laws to regulate office use Compounded IV Products. HR 3204; FDA jurisdic4on over compounding
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationSummary of ARV prescribing guidelines in London
Summary of ARV prescribing guidelines in London These slides summarise the recommenda1ons by the London HIV Consor1um for prescribing an1retrovirals. April 2011 HIV posi1ve people should discuss these
More informationWHO position paper on meningococcal vaccines
WHO position paper on meningococcal vaccines Geneva, Switzerland Published in WER Nov 2011 Epidemiology of meningococcal disease In most countries Neisseria meningi+dis is a leading cause of meningi)s
More informationInitial Resuscitation of Sepsis & Septic Shock
Initial Resuscitation of Sepsis & Septic Shock Dr. Fatema Ahmed MD (Critical Care Medicine) FCPS (Medicine) Associate professor Dept. of Critical Care Medicine BIRDEM General Hospital Is Sepsis a known
More informationAntimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections
Antimicrobial Guidelines for the Empirical Management of Diabetic Foot Infections Version 7.2 PAGL Inclusion Approved at January 2017 PGC APPROVED BY: TRUST REFERENCE: B3/2017 AWP REF: UHL Policies and
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationWhat works in sepsis. Topics. EGDT: Severe Sepsis/ Shock. Sepsis
What works in sepsis Eric Schmidt, MD Denver Health Medical Center University of Colorado School of Medicine Topics Understanding and implemen@ng early goal directed therapy (EGDT) Ac@vated Protein C should
More informationDiagnos(c U(lity of CRP in the ED. Joanna Middleton
Diagnos(c U(lity of CRP in the ED Joanna Middleton Objec(ves Review the u(lity of a CRP in diagnosing various ED condi(ons Discovery 1930 TilleF and Francis Substance in serum that reacted with C- polysaccharide
More informationEight Things to Do Differently Tomorrow. Learning Objec-ves. The Benefits of 3000 Common Medical Treatments
Eight Things to Do Differently Tomorrow Evidence Based Answers to Common Clinical Questions in Hospitalist Practice Chad R. Stickrath, MD October 10 th, 2014 Learning Objec-ves Understand the (new) evidence
More informationPatients at High Risk Experience, Guidelines, and Best Practices. Mozambique. José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe
Patients at High Risk Experience, Guidelines, and Best Practices Mozambique José Tique, MD MPH MoH July 17-19, 2017 Harare, Zimbabwe Content Scope of the Problem Treatment Guidelines Best Prac9ces Differen9a9ng
More informationThe Ever Changing World of Sepsis Management. Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital
The Ever Changing World of Sepsis Management Laura Evans MD MSc Medical Director of Critical Care Bellevue Hospital COI Disclosures No financial interests to disclose Learning Objectives Review the evolution
More informationTitle: Pharmacy sales data versus ward stock accounting for the surveillance of broad-spectrum antibiotic use in hospitals
Author's response to reviews Title: Pharmacy sales data versus ward stock accounting for the surveillance of broad-spectrum antibiotic use in hospitals Authors: Jon B. Haug (jobhau57@gmail.com) Randi Myhr
More informationSepsi: nuove definizioni, approccio diagnostico e terapia
GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva
More informationPreparing Pre-health Professional Students & Advisors for the Mul8ple Mini-Interviews: Advanced Issues
Preparing Pre-health Professional Students & Advisors for the Mul8ple Mini-Interviews: Advanced Issues Robert Klitzman, MD Professor of Psychiatry Director, Bioethics Masters & Online Certificate & Course
More informationMANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION
MANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION RRCV CMG Renal and Transplant Service 1. Introduction Catheter related blood stream infection (CR-BSI) is a common complication in patients
More information